Effectiveness of highly active antiretroviral therapy among HIV-1 infected women

Stephen J Gange, Y. Barrón, R. M. Greenblatt, K. Anastos, H. Minkoff, M. Young, A. Kovacs, M. Cohen, W. A. Meyer, Alvaro Munoz

Research output: Contribution to journalArticle

Abstract

Study objective: To describe the impact of highly active antiretroviral therapy (HAART) on mortality, morbidity, and markers of HIV disease progression in HIV infected women. Design: Data collected from the Women's Interagency HIV Study, a prospective cohort study that enrolled women between October 1994 and November 1995. Setting: Six clinical consortia based in five cities in the United States (New York, NY; Washington, DC; Los Angeles, CA; San Francisco, CA; and Chicago, IL). Participants: A total of 1691 HIV seropositive women with a study visit after April 1996. Main results: Beginning in April 1996, the self reported use of HAART increased over time, with more than 50% of the cohort reporting HAART use in 1999. There was a 23% decline per semester in the incidence of AIDS from April 1996 (95% confidence intervals (CI) -29% to -16%). Furthermore, there was a 21% decline of the semiannual mortality rates among those with AIDS at baseline (95% CI -27% to -14%) and an 11% decline among those AIDS free at baseline (95% CI -3% to -18%). CD4+ lymphocyte counts either increased (women with baseline AIDS) or stabilised (women without baseline AIDS) after April 1996, and HIV RNA levels dramatically declined in both groups, although the percentage of women with HIV RNA above 4000 cps/ml remained stable at approximately 40% since mid-1997. Conclusions: Despite concerns regarding the use of antiretroviral therapies in this population, the use of therapies led to improved immunological function, suppressed HIV disease activity, and dramatic declines in morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)153-159
Number of pages7
JournalJournal of Epidemiology and Community Health
Volume56
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Highly Active Antiretroviral Therapy
HIV-1
HIV
Acquired Immunodeficiency Syndrome
Confidence Intervals
Mortality
RNA
Morbidity
San Francisco
Los Angeles
CD4 Lymphocyte Count
Disease Progression
Cohort Studies
Prospective Studies
Incidence
Therapeutics
Population

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Effectiveness of highly active antiretroviral therapy among HIV-1 infected women. / Gange, Stephen J; Barrón, Y.; Greenblatt, R. M.; Anastos, K.; Minkoff, H.; Young, M.; Kovacs, A.; Cohen, M.; Meyer, W. A.; Munoz, Alvaro.

In: Journal of Epidemiology and Community Health, Vol. 56, No. 2, 2002, p. 153-159.

Research output: Contribution to journalArticle

Gange, SJ, Barrón, Y, Greenblatt, RM, Anastos, K, Minkoff, H, Young, M, Kovacs, A, Cohen, M, Meyer, WA & Munoz, A 2002, 'Effectiveness of highly active antiretroviral therapy among HIV-1 infected women', Journal of Epidemiology and Community Health, vol. 56, no. 2, pp. 153-159. https://doi.org/10.1136/jech.56.2.153
Gange, Stephen J ; Barrón, Y. ; Greenblatt, R. M. ; Anastos, K. ; Minkoff, H. ; Young, M. ; Kovacs, A. ; Cohen, M. ; Meyer, W. A. ; Munoz, Alvaro. / Effectiveness of highly active antiretroviral therapy among HIV-1 infected women. In: Journal of Epidemiology and Community Health. 2002 ; Vol. 56, No. 2. pp. 153-159.
@article{2c1092ec088243d4b7ef6da8e4e73c5e,
title = "Effectiveness of highly active antiretroviral therapy among HIV-1 infected women",
abstract = "Study objective: To describe the impact of highly active antiretroviral therapy (HAART) on mortality, morbidity, and markers of HIV disease progression in HIV infected women. Design: Data collected from the Women's Interagency HIV Study, a prospective cohort study that enrolled women between October 1994 and November 1995. Setting: Six clinical consortia based in five cities in the United States (New York, NY; Washington, DC; Los Angeles, CA; San Francisco, CA; and Chicago, IL). Participants: A total of 1691 HIV seropositive women with a study visit after April 1996. Main results: Beginning in April 1996, the self reported use of HAART increased over time, with more than 50{\%} of the cohort reporting HAART use in 1999. There was a 23{\%} decline per semester in the incidence of AIDS from April 1996 (95{\%} confidence intervals (CI) -29{\%} to -16{\%}). Furthermore, there was a 21{\%} decline of the semiannual mortality rates among those with AIDS at baseline (95{\%} CI -27{\%} to -14{\%}) and an 11{\%} decline among those AIDS free at baseline (95{\%} CI -3{\%} to -18{\%}). CD4+ lymphocyte counts either increased (women with baseline AIDS) or stabilised (women without baseline AIDS) after April 1996, and HIV RNA levels dramatically declined in both groups, although the percentage of women with HIV RNA above 4000 cps/ml remained stable at approximately 40{\%} since mid-1997. Conclusions: Despite concerns regarding the use of antiretroviral therapies in this population, the use of therapies led to improved immunological function, suppressed HIV disease activity, and dramatic declines in morbidity and mortality.",
author = "Gange, {Stephen J} and Y. Barr{\'o}n and Greenblatt, {R. M.} and K. Anastos and H. Minkoff and M. Young and A. Kovacs and M. Cohen and Meyer, {W. A.} and Alvaro Munoz",
year = "2002",
doi = "10.1136/jech.56.2.153",
language = "English (US)",
volume = "56",
pages = "153--159",
journal = "Journal of Epidemiology and Community Health",
issn = "0143-005X",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Effectiveness of highly active antiretroviral therapy among HIV-1 infected women

AU - Gange, Stephen J

AU - Barrón, Y.

AU - Greenblatt, R. M.

AU - Anastos, K.

AU - Minkoff, H.

AU - Young, M.

AU - Kovacs, A.

AU - Cohen, M.

AU - Meyer, W. A.

AU - Munoz, Alvaro

PY - 2002

Y1 - 2002

N2 - Study objective: To describe the impact of highly active antiretroviral therapy (HAART) on mortality, morbidity, and markers of HIV disease progression in HIV infected women. Design: Data collected from the Women's Interagency HIV Study, a prospective cohort study that enrolled women between October 1994 and November 1995. Setting: Six clinical consortia based in five cities in the United States (New York, NY; Washington, DC; Los Angeles, CA; San Francisco, CA; and Chicago, IL). Participants: A total of 1691 HIV seropositive women with a study visit after April 1996. Main results: Beginning in April 1996, the self reported use of HAART increased over time, with more than 50% of the cohort reporting HAART use in 1999. There was a 23% decline per semester in the incidence of AIDS from April 1996 (95% confidence intervals (CI) -29% to -16%). Furthermore, there was a 21% decline of the semiannual mortality rates among those with AIDS at baseline (95% CI -27% to -14%) and an 11% decline among those AIDS free at baseline (95% CI -3% to -18%). CD4+ lymphocyte counts either increased (women with baseline AIDS) or stabilised (women without baseline AIDS) after April 1996, and HIV RNA levels dramatically declined in both groups, although the percentage of women with HIV RNA above 4000 cps/ml remained stable at approximately 40% since mid-1997. Conclusions: Despite concerns regarding the use of antiretroviral therapies in this population, the use of therapies led to improved immunological function, suppressed HIV disease activity, and dramatic declines in morbidity and mortality.

AB - Study objective: To describe the impact of highly active antiretroviral therapy (HAART) on mortality, morbidity, and markers of HIV disease progression in HIV infected women. Design: Data collected from the Women's Interagency HIV Study, a prospective cohort study that enrolled women between October 1994 and November 1995. Setting: Six clinical consortia based in five cities in the United States (New York, NY; Washington, DC; Los Angeles, CA; San Francisco, CA; and Chicago, IL). Participants: A total of 1691 HIV seropositive women with a study visit after April 1996. Main results: Beginning in April 1996, the self reported use of HAART increased over time, with more than 50% of the cohort reporting HAART use in 1999. There was a 23% decline per semester in the incidence of AIDS from April 1996 (95% confidence intervals (CI) -29% to -16%). Furthermore, there was a 21% decline of the semiannual mortality rates among those with AIDS at baseline (95% CI -27% to -14%) and an 11% decline among those AIDS free at baseline (95% CI -3% to -18%). CD4+ lymphocyte counts either increased (women with baseline AIDS) or stabilised (women without baseline AIDS) after April 1996, and HIV RNA levels dramatically declined in both groups, although the percentage of women with HIV RNA above 4000 cps/ml remained stable at approximately 40% since mid-1997. Conclusions: Despite concerns regarding the use of antiretroviral therapies in this population, the use of therapies led to improved immunological function, suppressed HIV disease activity, and dramatic declines in morbidity and mortality.

UR - http://www.scopus.com/inward/record.url?scp=0036151783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036151783&partnerID=8YFLogxK

U2 - 10.1136/jech.56.2.153

DO - 10.1136/jech.56.2.153

M3 - Article

VL - 56

SP - 153

EP - 159

JO - Journal of Epidemiology and Community Health

JF - Journal of Epidemiology and Community Health

SN - 0143-005X

IS - 2

ER -